拉米夫定联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化临床疗效观察

Clinical efficacy of Lamivudine and Adefovir treatment in patients with decompensated liver cirrhosis resulting with hepatitis B

目的:观察拉米夫定联合阿德福韦酯治疗乙型肝炎肝硬化患者的临床疗效。方法:53例失代偿期乙型肝炎肝硬化患者在保肝、利尿和补充白蛋白等基础治疗的同时,给予拉米夫定100mg,1次/d口服,3个月后,加用阿德福韦酯10mg,1次/d口服,疗程48周。治疗结束时,观察血清ALT、HBVDNA及Child-Pugh评分变化。结果:治疗后HBVDNA阴转率为90.2%,肝功能指标即血清ALT水平及Child-Pugh评分明显改善。结论:拉米夫定联合阿德福韦酯治疗能明显改善乙型肝炎肝硬化患者的肝功能指标,不易产生耐药性,改善预后。

Objective： To evaluate the clinical efficacy of Lamivudine and Adefovir treatment in patients with decompensated liver cirrhosis resulting from hepatitis B. Methods： Fifty three patients with decompensated liver cirrhosis with hepatitis B were included with Lamivudine 100 mg and Adefovir 10 mg once daily for 48 weeks. Serum HBV DNA, hepatitis B serology markers, ALT level and Child-Pugh scores were measured after therapy. Results： The negative rate of HBV DNA was 90.2%. Liver function index including serum ALT level and the Child-Pugh scores improved obviously. Conclusion： Combination Lamivudine and Adefovir in treatment of decompensated liver cirrhosis resulting from hepatitis B has obvious effect on improving the liver function and outcomes.